Single agent therapy of interferon for brain tumours: correlation between natural killer activity and clinical course

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Interferon (IFN) is explored for its anti-tumour properties.
• Glioblastomas are aggressive brain tumors with limited treatment options.
• Natural killer (NK) cells play a role in anti-tumour immunity.

Purpose of the Study:

• To evaluate the anti-tumour effect of mouse interferon (IFN) on intracranial 203-glioma in C57BL mice.
• To assess the impact of human fibroblast IFN on glioblastoma patients.
• To investigate the correlation between IFN therapy, NK cell activity, and anti-tumour response.

Main Methods:

• In vivo studies using C57BL mice with transplanted 203-glioma.
• Clinical trial involving five glioblastoma patients treated with human fibroblast IFN.
• Measurement of NK cell activity in mouse spleen cells and human peripheral blood lymphocytes.

Main Results:

• IFN therapy led to an increase in NK cell activity in both mouse and human subjects.
• No significant anti-tumour effect of IFN was observed in the mouse glioma model.
• Limited anti-tumour efficacy of IFN was noted in glioblastoma patients.
• A clear correlation between elevated NK activity and the anti-tumour effect of IFN was not established.

Conclusions:

• While IFN therapy can enhance NK cell activity, it demonstrated limited efficacy against intracranial glioma in mice and glioblastomas in humans.
• Further research is needed to explore alternative or combined therapeutic strategies for glioblastoma.